Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inbox Gmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscription Click this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
This Week's Bonus Content Why Boston Scientific's Big Dip Could Be a Bigger OpportunitySubmitted by Nathan Reiff. Posted: 3/24/2026. 
Key Points - Boston Scientific shares are down over 25% year-to-date after investors may have been disappointed by the company's 2026 sales guidance.
- Still, there are many positives that could entice investors keen to buy the dip, including strong free cash flow growth and the prospect of access to new markets with the impending completion of the Penumbra acquisition.
- A potential major catalyst for growth is the Champion trial, which could significantly increase the addressable patient pool of Boston Scientific's Watchman line.
- Special Report: Elon Musk: This Could Turn $100 into $100,000
Medical device manufacturer Boston Scientific Corp. (NYSE: BSX) is off to a rough start: shares have fallen about 26% year-to-date and nearly a third over the past 12 months. Still, a closer look at the healthcare company's fundamentals shows some solid results — adjusted earnings per share (EPS) of $0.80 for the most recent quarter, $0.02 above consensus. Indeed, a detailed review of Boston Scientific's earnings suggests many parts of the business are performing well. Its electrophysiology (EP) segment — and Watchman products in particular — have grown rapidly and appear positioned for continued expansion. The company is also expected to release results from its Champion-AF trial by the end of March, which could materially expand the product's addressable patient population. Investors may be tempted to buy the dip in BSX stock, but it's important to understand why shares have fallen and what risks remain. Is the Boston Scientific Dip Justified? Shares of BSX plunged after the February earnings release, even though revenue rose about 16% year over year (YOY) and adjusted EPS beat expectations. Free cash flow also improved substantially, rising 38% YOY to roughly $3.7 billion. The selloff appears to reflect disappointment with the company's 2026 organic revenue guidance, which forecasts YOY growth of 10% to 11% — notably slower than 2025's roughly 20% full-year revenue growth. Part of the slowdown relates to the company's discontinuation of certain Axios catheter products and other lines early in the year. Management expects this will shave roughly 150 basis points off early‑2026 growth. That said, much of Boston Scientific's business remains intact and growing. The company expects another year of rising free cash flow — about $4.2 billion forecast for 2026 — along with ongoing operating margin expansion and improved efficiency metrics. The Champion Trial Could Be a Catalyst for Reversal One catalyst that could reverse the share-price slide is the Champion trial, which compares the company's Watchman stroke-reduction implant to oral anticoagulation treatments. Investors should watch these results closely, because a positive outcome could expand the addressable patient pool for Watchman to roughly 20 million — about four times the current estimate. If the trial is successful, the impact could be significant over several years, enabling global sales growth by adding millions of potential patients. Another potential growth driver is Boston Scientific's planned acquisition of neurovascular device maker Penumbra (NYSE: PEN). Penumbra's products would give Boston Scientific an entry into the mechanical thrombectomy market, an area where it currently lacks presence. The $14.5 billion deal is partly financed by a $6 billion term loan secured in late February. While the financing adds near-term pressure, Boston Scientific's rising free cash flow and strong underlying operations may help mitigate investor concerns. Risks and Analyst Perspectives Are Worth Keeping in Mind A negative Champion result would be a major risk: it could halt the expected acceleration in Watchman sales and undermine overall revenue growth plans, making the company's 10%–11% growth guidance for 2026 harder to achieve. Still, Wall Street remains broadly optimistic. Of 25 analyst ratings, 23 are Buys and two are Holds. Several firms, including Stifel Nicolaus, Jefferies, and Truist Financial, reissued Buy ratings in March, though some have trimmed price targets while maintaining their Buy calls. The consensus price target of $106.27 implies more than 50% upside from current levels, reflecting the market's expectation of meaningful long-term upside if the company executes on its catalysts and integration plans. | 
Post a Comment
Post a Comment